Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeGet StartedBook a Demo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Other EventsItem 8.01 · 8-KLOW RiskPositive

Summit Therapeutics Inc.

www.smmttx.com
Filed: Jul 22, 2026CIK: 0001599298Biotechnology
Full company profileView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Summit Therapeutics announced updated overall survival analysis results from its Phase III HARMONi trial showing promising trends for ivonescimab combined with chemotherapy in treating EGFR-mutated advanced non-small cell lung cancer, with consistent results across western and Asian patient populations.

Key Takeaways

Phase III HARMONi trial data shows consistent overall survival trends for ivonescimab plus chemotherapy versus placebo in previously treated EGFR-mutated non-small cell lung cancer patients

Analysis includes data from both western and Asian patient populations, demonstrating broad applicability of the treatment approach

2 more takeaways

Related Filings (1)

1 more filing from Summit Therapeutics Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateJul 22, 2026
Item8.01
CategoryOther Events
CIK0001599298
Accession #smmt-20260722
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
product launchregulatory

What This Means

Other material events not covered by specific item numbers. The content of the filing determines significance.
View Full Filing on SEC.govBrowse More Filings